| Title : Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities - Hirmas_2023_J.Nucl.Med_64_711 |
| Author(s) : Hirmas N , Hamacher R , Sraieb M , Ingenwerth M , Kessler L , Pabst KM , Barbato F , Lueckerath K , Kasper S , Nader M , Schildhaus HU , Kesch C , von Tresckow B , Hanoun C , Hautzel H , Aigner C , Glas M , Stuschke M , Kummel S , Harter P , Lugnier C , Uhl W , Niedergethmann M , Hadaschik B , Grunwald V , Siveke JT , Herrmann K , Fendler WP |
| Ref : J Nucl Med , 64 :711 , 2023 |
|
Abstract :
We present an overview of our prospective fibroblast-activation protein inhibitor (FAPI) registry study across a 3-y period, with head-to-head comparison of tumor uptake in (68)Ga-FAPI and (18)F-FDG PET, as well as FAP immunohistochemistry. Methods: This is an interim analysis of the ongoing (68)Ga-FAPI PET prospective observational trial at our department. Patients who underwent clinical imaging with (68)Ga-FAPI PET between October 2018 and October 2021 were included. Tracer uptake was quantified by SUV(max) for tumor lesions and by SUV(mean) for normal organs. PET tumor volume (40% isocontour) and tumor-to-background ratios were calculated. Correlation between SUV(max) and FAP staining in tissue samples was analyzed. Results: In total, 324 patients with 21 different tumor entities underwent (68)Ga-FAPI imaging; 237 patients additionally received (18)F-FDG PET. The most common tumor entities were sarcoma (131/324, 40%), pancreatic cancer (67/324, 21%), and primary tumors of the brain (22/324, 7%). The mean primary tumor SUV(max) was significantly higher for (68)Ga-FAPI than (18)F-FDG among pancreatic cancer (13.2 vs. 6.1, P < 0.001) and sarcoma (14.3 vs. 9.4, P < 0.001), and the same was true for mean SUV(max) in metastatic lesions of pancreatic cancer (9.4 vs. 5.5, P < 0.001). Mean primary tumor maximum tumor-to-background ratio was significantly higher for (68)Ga-FAPI than (18)F-FDG across several tumor entities, most prominently pancreatic cancer (14.7 vs. 3.0, P < 0.001) and sarcoma (17.3 vs. 4.7, P < 0.001). Compared with (18)F-FDG, (68)Ga-FAPI showed superior detection for locoregional disease in sarcoma (52 vs. 48 total regions detected) and for distant metastatic disease in both sarcoma (137 vs. 131) and pancreatic cancer (65 vs. 57), respectively. Among 61 histopathology samples, there was a positive correlation between (68)Ga-FAPI SUV(max) and overall FAP immunohistochemistry score (r = 0.352, P = 0.005). Conclusion: (68)Ga-FAPI demonstrates higher absolute uptake in pancreatic cancer and sarcoma, as well as higher tumor-to-background uptake along with improved tumor detection for pancreatic cancer, sarcoma, and other tumor entities when compared with (18)F-FDG. (68)Ga-FAPI is a new tool for tumor staging with theranostic potential. |
| PubMedSearch : Hirmas_2023_J.Nucl.Med_64_711 |
| PubMedID: 36581374 |
Hirmas N, Hamacher R, Sraieb M, Ingenwerth M, Kessler L, Pabst KM, Barbato F, Lueckerath K, Kasper S, Nader M, Schildhaus HU, Kesch C, von Tresckow B, Hanoun C, Hautzel H, Aigner C, Glas M, Stuschke M, Kummel S, Harter P, Lugnier C, Uhl W, Niedergethmann M, Hadaschik B, Grunwald V, Siveke JT, Herrmann K, Fendler WP (2023)
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
J Nucl Med
64 :711
Hirmas N, Hamacher R, Sraieb M, Ingenwerth M, Kessler L, Pabst KM, Barbato F, Lueckerath K, Kasper S, Nader M, Schildhaus HU, Kesch C, von Tresckow B, Hanoun C, Hautzel H, Aigner C, Glas M, Stuschke M, Kummel S, Harter P, Lugnier C, Uhl W, Niedergethmann M, Hadaschik B, Grunwald V, Siveke JT, Herrmann K, Fendler WP (2023)
J Nucl Med
64 :711